Clinical trial
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate…
NCT00171158 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00171158 |
|---|---|
| Title | An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis |
| Official title | An Extension to a Phase II Open-label Study to Determine the Safety and Anti-leukemic Effects of STI571 in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Myeloid Blast Crisis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Philadelphia Chromosome Positive CML |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 260 |
| Start date | Jul 26, 1999 |
| Primary completion | Apr 1, 2013 |
| Completion | Apr 22, 2013 |
| First posted | Sep 15, 2005 |
| Last update posted | Jun 25, 2021 |
| Countries | France, Germany, Italy, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: